trending Market Intelligence /marketintelligence/en/news-insights/trending/kbufXlpKYnQ5yVF24yCxaA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Vertex Pharmaceuticals sees 34% YOY jump in Q2 profit

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Vertex Pharmaceuticals sees 34% YOY jump in Q2 profit

Vertex Pharmaceuticals Inc.'s second-quarter non-GAAP net income totaled $1.26 per share, compared with the S&P Global Market Intelligence consensus normalized EPS estimate of $1.07 per share.

Non-GAAP net income totaled $327.0 million, up 34% from $244.0 million in the year-ago period. On a per-share basis, non-GAAP net income climbed 34% year over year from 94 cents.

Revenue saw a 25% increase to $940.0 million in the second quarter from $750.0 million in the same period a year ago, primarily driven by the uptake of Symdeko in the U.S. and Symkevi in Germany.

GAAP net income attributable to the Boston-based company rose 29% to $267.0 million, or $1.03 per share, from $207.0 million, or 80 cents per share. The company said GAAP net income for the period was driven by the strong growth in total product revenues. It was also affected by rising operating costs, including a $50 million up-front payment as part of Vertex's recent collaboration with Kymera Therapeutics LLC, and income taxes.

The U.S. biotechnology company expects total product revenue in the range of $3.60 billion to $3.70 billion for the full year 2019, up from the prior guidance of $3.45 billion to $3.55 billion.

The company said its board has authorized a share repurchase program of up to $500 million of common stock through Dec. 31, 2020, to reduce the impact of dilution from employee equity programs.